Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$163.79
+1.9%
$173.42
$130.96
$182.89
$290.01B0.615.46 million shs5.85 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$43.99
+0.7%
$50.37
$43.33
$69.10
$89.17B0.4514.31 million shs12.10 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.81
+0.4%
$26.88
$25.20
$40.37
$157.48B0.6341.90 million shs60.57 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$167.07
-0.1%
$168.88
$144.80
$201.92
$76.41B0.864.61 million shs3.01 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.84%+2.62%-7.63%-2.88%+9.76%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+0.66%-1.94%-15.71%-9.69%-33.99%
Pfizer Inc. stock logo
PFE
Pfizer
+0.40%+9.57%+2.13%+3.27%-27.67%
Zoetis Inc. stock logo
ZTS
Zoetis
-0.10%+5.46%+2.53%-11.62%-6.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.7356 of 5 stars
2.43.04.23.93.12.51.9
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9488 of 5 stars
4.14.02.54.02.91.71.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9788 of 5 stars
4.23.04.24.83.71.71.3
Zoetis Inc. stock logo
ZTS
Zoetis
4.9056 of 5 stars
3.55.04.20.42.52.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$174.316.42% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$60.0036.39% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0029.45% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
3.00
Buy$216.1329.36% Upside

Current Analyst Ratings

Latest PFE, BMY, ZTS, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/30/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$195.00 ➝ $180.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$195.00 ➝ $180.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $43.00
4/23/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$260.00 ➝ $230.00
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/16/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$220.00 ➝ $195.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.34$16.11 per share10.17$5.78 per share28.34
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B1.98$12.53 per share3.51$8.16 per share5.39
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.69$2.99 per share9.31$15.81 per share1.76
Zoetis Inc. stock logo
ZTS
Zoetis
$8.54B8.94$6.42 per share26.04$10.87 per share15.37

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3748.6013.582.0311.02%165.18%14.40%7/25/2024 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B-$3.10N/A6.2414.72-13.50%8.83%2.50%7/25/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.261.18-0.56%8.58%3.70%8/6/2024 (Estimated)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.34B$5.1932.1926.352.6227.38%50.74%17.68%8/13/2024 (Estimated)

Latest PFE, BMY, ZTS, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 24
Zoetis Inc. stock logo
ZTS
Zoetis
$1.34$1.38+$0.04$1.45$2.14 billion$2.19 billion      
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/26/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion      
4/25/2024Q1 24
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.53-$4.40+$0.13$9.69$11.45 billion$11.87 billion      
2/13/202412/31/2023
Zoetis Inc. stock logo
ZTS
Zoetis
$1.32$1.24-$0.08$1.34$2.19 billion$2.21 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.79%+7.84%183.98%52 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.46%+8.20%N/A N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.04%+2.57%N/A 15 Years
Zoetis Inc. stock logo
ZTS
Zoetis
$1.731.04%+23.31%33.33%12 Years

Latest PFE, BMY, ZTS, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/6/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Quarterly$0.43200.88%4/18/20244/19/20246/4/2024
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.99
1.11
0.99
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69
Zoetis Inc. stock logo
ZTS
Zoetis
1.32
3.36
2.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Zoetis Inc. stock logo
ZTS
Zoetis
0.16%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.03 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,100457.36 million456.63 millionOptionable

BMY, ZTS, PFE, and ABBV Headlines

SourceHeadline
Victory Capital Management Inc. Sells 5,599 Shares of Zoetis Inc. (NYSE:ZTS)Victory Capital Management Inc. Sells 5,599 Shares of Zoetis Inc. (NYSE:ZTS)
marketbeat.com - May 4 at 7:56 AM
Zoetis (NYSE:ZTS) Shares Up 0.5% Following Earnings BeatZoetis (NYSE:ZTS) Shares Up 0.5% Following Earnings Beat
americanbankingnews.com - May 4 at 3:12 AM
Amalgamated Bank Sells 6,242 Shares of Zoetis Inc. (NYSE:ZTS)Amalgamated Bank Sells 6,242 Shares of Zoetis Inc. (NYSE:ZTS)
marketbeat.com - May 3 at 11:12 PM
Zoetis (ZTS) Q1 2024 Earnings Call TranscriptZoetis (ZTS) Q1 2024 Earnings Call Transcript
fool.com - May 3 at 11:03 PM
Zoetis Inc. (NYSE:ZTS) Q1 2024 Earnings Call TranscriptZoetis Inc. (NYSE:ZTS) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 3 at 11:03 PM
Zoetis (NYSE:ZTS) Issues FY 2024 Earnings GuidanceZoetis (NYSE:ZTS) Issues FY 2024 Earnings Guidance
marketbeat.com - May 3 at 5:27 PM
Zoetis (NYSE:ZTS) Shares Up 0.5% After Better-Than-Expected EarningsZoetis (NYSE:ZTS) Shares Up 0.5% After Better-Than-Expected Earnings
marketbeat.com - May 3 at 4:32 PM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTSROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS
prnewswire.com - May 3 at 3:08 PM
Zoetis: Long-Term Buy Despite Safety ConcernsZoetis: Long-Term Buy Despite Safety Concerns
seekingalpha.com - May 3 at 2:37 PM
Zoetis Inc (ZTS) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic Wins ...Zoetis Inc (ZTS) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic Wins ...
finance.yahoo.com - May 3 at 7:42 AM
Zoetis First Quarter 2024 Earnings: Beats ExpectationsZoetis First Quarter 2024 Earnings: Beats Expectations
finance.yahoo.com - May 3 at 7:42 AM
Zoetis (NYSE:ZTS) Shares Up 6% on Earnings BeatZoetis (NYSE:ZTS) Shares Up 6% on Earnings Beat
americanbankingnews.com - May 3 at 3:18 AM
Q1 2024 Zoetis Inc Earnings CallQ1 2024 Zoetis Inc Earnings Call
finance.yahoo.com - May 3 at 12:01 AM
Zoetis Inc. (NYSE:ZTS) Position Increased by Raymond James Financial Services Advisors Inc.Zoetis Inc. (NYSE:ZTS) Position Increased by Raymond James Financial Services Advisors Inc.
marketbeat.com - May 2 at 8:37 PM
Why Zoetis Stock Popped by Almost 6% on ThursdayWhy Zoetis Stock Popped by Almost 6% on Thursday
fool.com - May 2 at 4:56 PM
Why Animal Health-Focused Zoetis Shares Are Trading Higher TodayWhy Animal Health-Focused Zoetis Shares Are Trading Higher Today
msn.com - May 2 at 2:00 PM
Zoetis gains as Q1 beat addresses concerns over arthritis drugsZoetis gains as Q1 beat addresses concerns over arthritis drugs
msn.com - May 2 at 2:00 PM
Zoetis (ZTS) Q1 Earnings and Revenues Surpass EstimatesZoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
zacks.com - May 2 at 1:36 PM
ZTS Stock Earnings: Zoetis Beats EPS, Beats Revenue for Q1 2024ZTS Stock Earnings: Zoetis Beats EPS, Beats Revenue for Q1 2024
investorplace.com - May 2 at 1:04 PM
Zoetis (NYSE:ZTS) Stock Price Up 6% on Earnings BeatZoetis (NYSE:ZTS) Stock Price Up 6% on Earnings Beat
marketbeat.com - May 2 at 11:39 AM
Zoetis (NYSE:ZTS) Releases  Earnings Results, Beats Estimates By $0.04 EPSZoetis (NYSE:ZTS) Releases Earnings Results, Beats Estimates By $0.04 EPS
marketbeat.com - May 2 at 11:15 AM
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key MetricsCompared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
zacks.com - May 2 at 10:36 AM
Zoetis (NYSE:ZTS) Issues FY24 Earnings GuidanceZoetis (NYSE:ZTS) Issues FY24 Earnings Guidance
marketbeat.com - May 2 at 9:38 AM
Zoetis (ZTS) Beats Q1 Earnings and Revenue EstimatesZoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
zacks.com - May 2 at 9:11 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Zoetis logo

Zoetis

NYSE:ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.